Psychological factors and neuroleptic therapy: Some neglected issues

References

• Alanen Y. O., Rakkolainen V., Laakso J., Rasimus R., Kaljonen A. Towards Needs-specific Treatment of Schizophrenic Psychoses. Springer-Verlag, New York 1986
   Google Scholar
• Altman H., Brown M. L., Sletten I. W. “And … silently steal away” a study of elopers. Diseases of the Nervous System 1972; 33: 52–58
   PubMedGoogle Scholar
• Baekeland F., Lundwall L. Dropping out of treatment: a critical review. Psychological Bulletin 1975; 82: 735–783
   Google Scholar
• Bartko G., Herczeg I., Zador G. Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatrica Scandinavica 1988; 77: 74–76
   PubMed Web of Science ®Google Scholar
• Bentall R. P., Haddock G., Slade P. D. Cognitive behavior therapy for persistent auditory hallucinations: from theory to therapy. Behavior Therapy 1994; 25: 51–66
   Web of Science ®Google Scholar
• Boczkowski J. A., Zeichner A., Desanto N. Neuroleptic compliance among chronic schizophrenic outpatients. Journal of Consulting and Clinical Psychology 1985; 53: 666–671
   PubMed Web of Science ®Google Scholar
• Bollini P., Pampallona S., Orza M. J., Adams M. E., Chalmers T. C. Antipsychotic drugs: is more worse? A meta analysis of the published randomized controlled trials. Psychological Medicine 1994; 24: 307–316
   PubMed Web of Science ®Google Scholar
• Bowers M. B., Swigar M. E. Psychotic patients who become worse on neuroleptics. Journal of Clinical Psychopharmacology 1988; 8: 417–421
   PubMedGoogle Scholar
• Brett-Jones J., Garety P., Hemsley D. R. Measuring delusional experiences: A method and its application. British Journal of Clinical Psychology 1987; 26: 257–265
   PubMed Web of Science ®Google Scholar
• Brown, Herz. Response to neuroleptic drugs as a device for classifying schizophrenia. Schizophrenia Bulletin 1989; 15: 123–128
   PubMed Web of Science ®Google Scholar
• Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica 1963; 20: 140–144
   PubMedGoogle Scholar
• Carpenter W. T., Heinrichs D. W. Early intervention and time-limited targeted pharmacotherapy of schizophrenia. Schizophrenia Bulletin 1983; 9: 533–535
   PubMed Web of Science ®Google Scholar
• Conrad C. The meaning of medications: Another look at compliance. Social Science and Medicine 1985; 20: 29–37
   PubMed Web of Science ®Google Scholar
• Corrigan P. W., Liberman R. P., Engel J. D. From non-compliance to collaboration in the treatment of schizophrenia. Hospital and Community Psychiatry 1990; 41: 1203–1211
   PubMedGoogle Scholar
• Crow T. J., MacMillan J. F., Johnson A. L., Johnstone E. C. The Northwick Park study of first episodes of schizophrenia II: A controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986; 148: 120–127
   PubMed Web of Science ®Google Scholar
• Croyden-Smith A. Schizophrenia and madness. George Allen & Unwin, Herts 1982
   Google Scholar
• Davis K. L., Estess F. M., Simonton S. C., Gonda T. A. Effects of payment mode on clinical attendance and rehospitalization. American Journal of Psychiatry 1977; 134: 576–578
   PubMedGoogle Scholar
• Day J. C., Bentall R. P., Warner S. Schizophrenic patients' experience of neuroleptic medication: A social constructionist approach, (in preparation)
   Google Scholar
• Day J. C., Wood G., Dewey M., Bentall R. P. A self-rating scale for measuring neuroleptic side effects: Validation in a group of schizophrenic patients. British Journal of Psychiatry, (in press)
   Google Scholar
• Delay J., Deniker P., Harl J. M. Utilisation en therapeutique psychiatrique d'une phenothiazine d'action centrale elective. Annals of Medical Psychology 1952; 2: 112–117
   Google Scholar
• Diamond R. Drugs and the quality of life: The patients' point of view. Journal of Clinical Psychiatry 1985; 46: 29–35
   PubMed Web of Science ®Google Scholar
• Earl-Boyer E. A., Serper M. R., Davidson M., Harvey P. D. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance. Psychiatry Research 1991; 37: 47–56
   PubMedGoogle Scholar
• Eckman T. A., Liberman R. P. A large-scale field test of a medication management skills training program for people with schizophrenia. Psychosocial Rehabilitation Journal 1990; 13: 31–35
   Google Scholar
• Edwards J. G. The untoward effects of antipsychotic drugs: pathogenesis and management. The psychopharmacology and management of schizophrenia, P. B. Bradley, S. R. Hirsch. Oxford University Press, Oxford 1986
   Google Scholar
• Falloon I. R., Boyd J., McGill C. The family care of schizophrenia. Guilford Press, New York 1984
   Google Scholar
• Falloon I. R. H., Liberman R. P. Interactions between drug and psychosocial therapy in schizophrenia. Schizophrenia Bulletin 1983; 9: 543–554
   PubMed Web of Science ®Google Scholar
• Fallsberg M. Reflections on medicine and medication: a qualitative analysis among people on long-term drug regimes. London 1992, 7th Social Pharmacy Workshop
   Google Scholar
• Finn S. E., Bailey J. M., Schultz R. T., Faber R. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychological Medicine 1990; 35: 843–848
   Web of Science ®Google Scholar
• Frank A. F., Gunderson J. G. The role of therapeutic alliance in the treatment of schizophrenia. Archives of General Psychiatry 1990; 47: 228–236
   PubMed Web of Science ®Google Scholar
• Green J. H. Frequent rehospitalisation and non-compliance with treatment. Hospital and Community Psychiatry 1988; 39: 963–966
   PubMedGoogle Scholar
• Harris G. T. The relationship between neuroleptic drug dose and the performance of psychiatric patients in a maximum security token economy program. Journal of Behavior Therapy and Experimental Psychiatry 1989; 20: 57–67
   PubMedGoogle Scholar
• Harvey P. D., Pedley M. Auditory and visual distractability in schizophrenia: Clinical and medication status correlations. Schizophrenia Research 1989; 2: 295–300
   PubMed Web of Science ®Google Scholar
• Herz M. I., Glazer W. M., Mostert M. A., Sheard M. A., Szymanski H. V., Hafez H., Mirza M. J. V. Intermittent vs maintenance medication in schizophrenia. Archives of General Psychiatry 1991; 48: 333–339
   PubMed Web of Science ®Google Scholar
• Hirsch S. R. Clinical treatment of schizophrenia. The Psychopharmocology and Treatment of Schizophrenia, P. B. Bradley, S. R. Hirsch. Oxford University Press, Oxford 1986; 286–339
   Google Scholar
• Hogan T. P., Awad A. G., Eastwood R. A self-report scale predicitive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 1983; 13: 177–183
   PubMed Web of Science ®Google Scholar
• Hoge S. K., Appelbaum P. S., Lawlor T., Beck J. C., Litman R., Greer A., Gutheil T. G., Kaplan E. A prospective, multicenter study of patients' refusal of antipsychotic medication. Archives of General Psychiatry 1990; 47: 949–956
   PubMed Web of Science ®Google Scholar
• Irwin D. S., Weitzel W. D., Morgan D. W. Phenothiazine intake and staff attitudes. American Journal of Psychiatry 1971; 127: 1631–1635
   PubMed Web of Science ®Google Scholar
• Jeste D. V., Wyatt R. J. In search of treatment of tardive dyskinesia: review of the literature. Schizophrenia Bulletin 1979; 5: 251–293
   PubMed Web of Science ®Google Scholar
• Johnstone L. Family management of “schizophrenia”: Its assumptions and contradictions. Journal of Mental Health 1993; 2: 255–269
   Google Scholar
• Jolley A. G., Hirsch S. R., Morrison E., McRink A., Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. British Medical Journal 1990; 301: 837–842
   PubMed Web of Science ®Google Scholar
• Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry 1988; 45: 789–796
   PubMed Web of Science ®Google Scholar
• Kane J. M. Compliance issues in outpatient treatment. Journal of Clinical Psychopharmacology 1985; 5: 22–27
   Web of Science ®Google Scholar
• Karasu T. Psychotherapy and pharmacotherapy: Towards an integrative model. American Journal of Psychiatry 1982; 139: 1102–1113
   PubMed Web of Science ®Google Scholar
• Karon B. P. The fear of reducing medication, and where have all the patients gone?. Schizophrenia Bulletin 1984; 10: 613–617
   PubMed Web of Science ®Google Scholar
• Kelly G. R., Scott J. E. Medication compliance and health education among chronic outpatients with mental disorders. Medical Care 1990; 28: 1181–1197
   PubMed Web of Science ®Google Scholar
• Kingdon D., Turkington D., John C. Cognitive behaviour therapy of schizophrenia: the amenability of delusions and hallucinations to reasoning. British Journal of Psychiatry 1994; 164: 581–587
   PubMed Web of Science ®Google Scholar
• Kleinman I., Schacter D., Koritar E. Informed consent and tardive dyskinesia. American Journal of Psychiatry 1989; 146: 902–904
   PubMed Web of Science ®Google Scholar
• Leff J., Kuipers L., Berkowitz R., et al. A controlled trial of social intervention in the families of schizophrenic patients. British Journal of Psychiatry 1982; 141: 121–134
   PubMed Web of Science ®Google Scholar
• Leff J., Vaughan C. The role of maintenance therapy and relatives' expressed emotion in relapse of schizophrenia. A two-year follow up. British Journal of Psychiatry 1981; 139: 102–104
   PubMed Web of Science ®Google Scholar
• Leff J. P., Wing J. K. Trial of maintenance therapy in schizophrenia. British Medical Journal 1971; 3: 599–604
   PubMed Web of Science ®Google Scholar
• Leonard B. E. Fundamentals of Psychopharmacology. John Wiley, Chichester 1992
   Google Scholar
• Lieberman J. A. Understanding the mechanism of action of atypical antipsychotic drugs, a review of compounds in use and development. British Journal of Psychiatry 1993; 163: 7–18
   Google Scholar
• Lin I. F., Spiga R., Fortsch W. Insight and adherence to medication in chronic schizophrenics. Journal of Clinical Psychiatry 1979; 40: 430–432
   PubMed Web of Science ®Google Scholar
• Lingjaerde O., Ahlfors V. G., Dech P., Dencker S. J., Elgen K. The UKU side effect rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic treated patients. Acta Psychiatrica Scandinavica Supplementum 1987; 334(76)
   PubMedGoogle Scholar
• Lukoff D., Liberman R. P., Nuechterlein K. H. Symptom monitoring in the rehabilitation of schizophrenic patients. Schizophrenia Bulletin 1986; 12: 578–593
   PubMed Web of Science ®Google Scholar
• Mason A. S., Forrest I. S., Forrest F. W., Butler H. Adherance to maintenance therapy and rehospitalization. Diseases of the Nervous System 1963; 24: 103–104
   Google Scholar
• McKeown B., Thomas D. Q methodology. Sage, Beverley Hills 1988
   Google Scholar
• Miller W. R. Motivation for treatment: a review with special emphasis on alcoholism. Psychological Bulletin 1985; 98: 84–107
   PubMed Web of Science ®Google Scholar
• Miller W. R., Benefield R. G., Tonigan J. S. Enhancing motivation for change in problem drinking: a controlled comparison of two therapist styles. Journal of Consulting and Clinical Psychology 1993; 61: 455–461
   PubMed Web of Science ®Google Scholar
• Morley S. Single case research. Behavioural and mental health research: Handbook of skills and methods, G. Parry, F. N. Watts. Lawrence Erlbaum, Hove 1989; 233–264
   Google Scholar
• Mueser K. T., Berenbaum H. Psychodynamic treatment of schizophrenia: Is there a future?. Psychological Medicine 1990; 20: 253–262
   PubMed Web of Science ®Google Scholar
• Myers E. D. Age, persistence and improvement in an outpatient group. British Journal of Psychiatry 1975; 127: 157–159
   PubMedGoogle Scholar
• Nelson A., Gold B., Hutchinson R., Benezra E. Drug default among schizophrenic patients. American Journal of Hospital Pharmacy 1975; 32: 1237–1242
   PubMedGoogle Scholar
• Piatkowsa O., Farnill D. Medication—compliance or alliance? A client centred approach to increasing adherence. Schizophrenia: An Overview and Practical Handbook, D. J. Kavanagh. Chapman and Hall, London 1992
   Google Scholar
• Raynes A. E., Patch V. D. Distinguishing features of patients who discharge themselves from a psychiatric ward. Comprehensive Psychiatry 1971; 12: 473–479
   PubMed Web of Science ®Google Scholar
• Rogers A., Pilgrim D., Lacey R. Experiencing Psychiatry: Users' Views of Services. Macmillan in association with MIND Publications, London 1993
   Google Scholar
• Royal College of Psychiatrists. Consensus Statement on the Use of High Dose Antipsychotic Medication. Royal College of Psychiatrists. 1993
   Google Scholar
• Seltzer A., Roncari I., Garfinkel P. Effect of patient education on medication compliance. Canadian Journal of Psychiatry 1980; 25: 638–645
   PubMed Web of Science ®Google Scholar
• Spohn H. E., Strauss M. E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology 1989; 98: 367–380
   PubMed Web of Science ®Google Scholar
• Stainton Rogers W. Explaining Health and Illness: An Exploration of Diversity. Harvester Wheatsheaf, London 1991
   Google Scholar
• Starmark J. E., Forsman A., Wahlstrom J. Abscesses following prolonged intramuscular administration of perphenazine enantate. Acta Psychiatrica Scandinavica 1980; 62: 154–157
   PubMedGoogle Scholar
• Stephenson W. Technique of factor analysis. Nature 1935; 136: 297
   Google Scholar
• Sunahara R. K., Seeman P., Van Tol H. H. M., Niznik H. B. Dopamine receptors and antipsychotic drug response. British Journal of Psychiatry 1993; 163(Supplement)31–38
   Google Scholar
• Tarrier N., Beckett R., Harwood S. A trial of two cognitive-behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients I: Outcome. British Journal of Psychiatry 1993; 162: 524–532
   PubMed Web of Science ®Google Scholar
• Tyrer P., Smith J., Adshead G. Ethical dilemmas in drug treatments. Psychiatric Bulletin 1994; 18: 203–204
   Google Scholar
• Van Kammen D. P. The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis. Psychological Medicine 1991; 21: 881–895
   PubMedGoogle Scholar
• Van Putten T., Marder S. R., Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry 1990; 47: 754–758
   PubMed Web of Science ®Google Scholar
• Van Putten T., May P. R. Subjective response as a predictor of outcome in pharmacotherapy. Archives of General Psychiatry 1978; 35: 477–480
   PubMed Web of Science ®Google Scholar
• Van Putten T., May P. R., Marder S. R., Wittman L. A. Subjective response to antipsychotic drugs. Archives of General Psychiatry 1981; 38: 187–190
   PubMed Web of Science ®Google Scholar
• Vaughn C., Leff J. P. Influence of family and social factors on the course of psychiatric illness. British Journal of Psychiatry 1976; 129: 125–137
   PubMed Web of Science ®Google Scholar
• Warner R. Recovery from Schizophrenia. Psychiatry and Political Economy. Routledge & Kegan Paul, New York 1985
   Google Scholar
• Winkelman N. W. A clinical and socio-cultural study of 200 psychiatric patients started on chlorpromazine 10.5 years ago. American Journal of Psychiatry 1964; 120: 861–869
   PubMedGoogle Scholar